

Scott T. Tagawa, MD

Date of Birth: December 21, 1970
Place of Birth: Inglewood, CA
Nationality: U.S. Citizen

Address: Weill Cornell Medical College
Division of Hematology and Medical Oncology
525 E. 68th St., Box 403
New York, NY 10065

Phone: 646 962-2072
Fax: 646 962-1603
Email: stt2007@med.cornell.edu

Academic Appointments

Chief Resident, University of Southern California Department of Medicine, Los Angeles, CA.
July 2001 – June 2002.

Assistant Professor of Medicine, Division of Hematology & Oncology, Department of Medicine,
Mount Sinai School of Medicine, New York, NY
August 2005 – March 2007

Associate Director, Hematology/Oncology Fellowship Program, Mount Sinai School of
Medicine, New York, NY
January 2006 – March 2007

Assistant Professor of Medicine & Urology, Weill Cornell Medical College, New York, NY
April 2007 –

Hospital Appointments

Attending Physician, Hospitalist, Lakewood Regional Medical Center, Lakewood, CA.
December, 2001 – September 2002

Attending Staff Physician, Los Angeles County + University of Southern California Medical
Center, Los Angeles, CA. July, 2001 – June, 2005

Assistant Attending Staff Physician, Mount Sinai Medical Center, New York, NY
September 2005 – March 2007

Assistant Attending Physician, New York-Presbyterian Hospital, New York, NY
April 2007 –

Consultant, Hospital for Special Surgery, New York, NY
Sept 2010 –

Education

Georgetown University, Washington D.C. B.S., 1993. Biology major, economics minor.
University of Southern California School of Medicine. Los Angeles, CA. M.D., 1998.
Weill Cornell Graduate School of Medical Sciences, New York, NY. M.S. in Clinical
Investigation, 2010

Scott T. Tagawa, MD

Postdoctoral Training

Internship, Internal Medicine. University of Southern California Department of Medicine, June 1998 – June 1999.

Residency, Internal Medicine. University of Southern California Department of Medicine, July 1999 – June 2001.

Fellowship, Combined program in hematology and oncology. University of Southern California Department of Medicine, Divisions of Hematology and Oncology, July 2002 – June 2005.

Chief Fellow, Hematology 2003-04

Chief Fellow, Oncology 2004-05

Certification

Diplomat, American Board of Internal Medicine, Internal Medicine, August 2001

Diplomat, American Board of Internal Medicine, Medical Oncology, November 2005

Diplomat, American Board of Internal Medicine, Hematology, November 2006

Licensure

Physician, State of New York.

Honors/Awards/Patents

Deans List Scholar, Georgetown University College of Arts and Sciences Dean's List Scholar, 1989, 1992

Mid-Atlantic Academic All Conference Water Polo, Georgetown University, 1993

Dean's Scholar for the Junior/Senior Continuum, University of Southern California School of Medicine, 1998

Intern of the Year, USC Department of Medicine, 1999

Junior Resident of the Year, USC Department of Medicine, 2000

Senior Resident of the Year, USC Department of Medicine, 2001

Brautbar Teaching Award, USC Department of Medicine, 2001

Teacher of the Year, Division of Hematology, USC Department of Medicine, 2004

Chiron Immunotherapy Research Fellowship Award, 2004-05

Young Investigator Award, Prostate Cancer Foundation 2008-11

Super Doctors New York 2009, 2010, 2011, 2012

America's Top Doctors for Cancer – Volume 5 (Castle-Connolly 2009)

Top Doctors: New York Metro Area (13th, 14th, 15th Ed)

WCMC Department of Medicine Investigator Award Runner Up 2010

Guide to America's Top Oncologists 2010 (Consumer Research Council)

America's Top Doctors for Cancer – Volume 7 (Castle-Connolly 2011)

US News & World Report Top Doctors 2011

Other Professional Appointments

Director, Medical Oncology, Deane Prostate Health & Research Center, Mount Sinai Hospital

Scott T. Tagawa, MD

August 2005 – March 2007

Director, Genitourinary Oncology, Division of Hematology & Oncology, Department of Medicine, Mount Sinai School of Medicine

January 2006 – March 2007

Institutional Review Board, Mount Sinai School of Medicine

January 2006 – March 2007

Protocol Review Committee, Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College

April 2007 –

Fellowship Steering Committee, Division of Hematology & Medical Oncology, Department of Medicine, Weill Cornell Medical College

April 2007 –

Ad Hoc Reviewer, Audit Committee, Cancer and Leukemia Group B

June, 2007 –

Course Director, Clinical Oncology, Weill Cornell Medical College

December, 2007 –

Medical Director, Genitourinary Oncology Clinical Research Program, Division of Hematology & Medical Oncology, Weill Cornell Medical College, New York, NY

July 2010 –

Co-Chair, Genitourinary Working Group, New York Cancer Consortium

August 2010 –

Grant and Contract Support

Current Support:

Prostate Cancer Foundation

09/01/2008 – 08/31/2012

Radioimmunotherapy using anti-prostate specific membrane antigen-based monoclonal antibody (J591) for progressive castrate resistant prostate cancer

PCF Young Investigator Award

Role: Principal Investigator

\$225,000 (direct) over 3 years

PC081664

08/17/2009 – 08/16/2012

Department of Defense Prostate Cancer Research Program

A Randomized Phase 2 Trial of ¹⁷⁷Lu Radiolabeled Monoclonal Antibody HuJ591 (¹⁷⁷Lu-J591) and ketoconazole in Patients with High-Risk Castrate Biochemically Relapsed Prostate Cancer

After Local Therapy

Clinical Trial Award

Role: Principal Investigator

\$750,000 (direct) over 3 years

PTBF5405

10/01/2009 – 09/30/2013

NIH Loan Repayment Program, Clinical Research (Extramural)

Anti-PSMA-based therapy for prostate cancer

Role: Principal Investigator

Scott T. Tagawa, MD

Elsa U. Pardee Foundation 2/1/2010 – 6/31/2012
Radiolabeled anti-PSMA monoclonal antibody to target non-prostate solid tumor neovasculature
Role: Principal Investigator
\$116,853 (direct)

Past Support:

1-KL2-RR024997-01 02/01/2008 – 01/31/2010
Clinical and Translation Science Center at Weill Cornell Medical College
Anti-PSMA based Radioimmunotherapy for Prostate Cancer
K12 Clinical & Translational Research Training Scholars Award Program
Role: Principal Investigator
\$243,072 (direct) over 2 years

DOD Prostate Cancer Research Program Banck, M (PI)
Molecular mechanisms of the KLF6 tumor suppressor in prostate cancer.
Physician Research Training Award
Role: Co-investigator

Publications

Peer Reviewed Contributions

1. **Tagawa ST**, Lee P, Snively J, Boswell W, Ounparseuth S, Lee S, Hickingbottom B, Smith J, Johnson D, Weber JS. Phase I study of intranodal delivery of a plasmid DNA vaccine for stage IV melanoma. *Cancer* 98: 144-154, 2003.
2. Israel V*, **Tagawa ST***, Snyder T, Jeffers S, Raghavan D. Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer. *Investigational New Drugs* 2004; 22: 291-297.
*Drs. Israel and Tagawa contributed equally to the publication of this study and should be regarded for academic and tenure purposes as joint first authors.
3. **Tagawa ST**, Cheung E, Banta W, Gee C, Weber JS. Survival analysis after resection of metastatic disease followed by peptide vaccines in stage IV melanoma. *Cancer* 2006; 106: 1353-7.
4. **Tagawa ST**, Dorff TB, Rochanda L, Ye W, Boyle S, Raghavan D, Lieskovsky G, Skinner DG, Quinn DI, Liebman HA. Subclinical hemostatic activation and surgeon volume predict bleeding with open radical retropubic prostatectomy. *BJU Int* 2008; 102(9): 1086-91.
5. **Tagawa ST**, Beltran H, Vallabhajosula S, Goldsmith SJ, Osborne J, Matulich D, Petrillo K, Parmar S, Nanus DM, Bander NH. Anti-Prostate Specific Membrane Antigen-based Radioimmunotherapy for Prostate Cancer. *Cancer* 2010; 116(4 suppl): 1075-83.
6. Gleghorn JP, Pratt ED, Denning D, Liu H, Bander NH, **Tagawa ST**, Nanus DM, Giannakakou PA, Kirby BJ. Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody. *Lab Chip* 2010; 10: 27-29.

Scott T. Tagawa, MD

7. Jeske S, **Tagawa ST**, Olowokure O, Selzer J, Giannakakou P, Nanus DM. Carboplatin Plus Paclitaxel Therapy after Docetaxel in Men with Metastatic Castrate Resistant Prostate Cancer. *Urol Oncol* 2010 May 5; E pub ahead of print
8. **Tagawa ST**, Milowsky MI, Jeske S, Mazumdar M, Kung S, Sung M, Lehrer D, Matulich D, Selzer J, Wright JJ, Nanus DM. A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma (New York Cancer Consortium trial NCI 6981). *Am J Clin Oncol* 2010; Sep 24 [Epub ahead of print]
9. Beltran H, Robinson BD, **Tagawa ST**. Primary Squamous Cell Carcinoma of the Urinary Bladder Presenting as Peritoneal Carcinomatosis. *Adv Urol* 2010; article ID 179250.
10. Schöffski P, Garcia JA, Stadler WM, Gil T, Jonasch E, **Tagawa ST**, Smitt M, Yang X, Oliner KS, Anderson A, Zhu M, Kabbinavar K. A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. *BJU Int* 2010; Dec 13 [Epub ahead of print]
11. Bouchelouche K, **Tagawa ST**, Goldsmith SJ, Turkbey B, Capala J, Choyke P. PET/CT imaging and radioimmunotherapy of prostate cancer. *Sem Nuc Med* 2011; 41: 29-44.
12. Beltran H, Beer T, Carducci MA, de Bono J, Gleave M, Hussain M, Kelly WK, Saad F, Sternberg C, **Tagawa ST**, Tannock IF. New therapies for castration-resistant prostate cancer: Efficacy and safety. *European Urology* 2011; 60(2): 279-90.
13. Akhtar NH, Pail O, Saran A, Tyrell L, **Tagawa ST**. Prostate-specific membrane antigen-based therapeutics. *Adv Urol* 2012; article ID 973820
14. Darshan MS, Loftus MS, Thadani-Mulero M, Levy BP, Escuin D, Zhou XK, Gjyzezi A, Chanel-Vos C, Shen R, **Tagawa ST**, Bander NH, Nanus DM, Giannakakou P. Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer. *Cancer Res* 2011; Jul 28. [Epub ahead of print]
15. Beltran H, Rickman DS, Park K, Sboner A, MacDonald TY, Wang Y, Chae SS, Sheikh K, Terry S, **Tagawa ST**, Dhir R, Nelson J, de la Taille A, Allory Y, Gerstein MB, Perner S, Pienta K, Chinnaiyan A, Wang Y, Collins C, Gleave M, Demichelis F, Nanus DM, Rubin MA. Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets. *Cancer Discovery* 2011, *Epub ahead of print*
16. Smith MJ, Akhtar NH, **Tagawa ST**. The Current Role of Androgen Deprivation in Patients Undergoing Dose-Escalated External Beam Radiation Therapy for Clinically Localized Prostate Cancer. *Prostate Cancer* 2012, *in press*
17. Kosuri S, Akhtar NH, Smith MJ, Osborne J, **Tagawa ST**. Review of salvage therapy for biochemically recurrent prostate cancer: The role of imaging and rationale for systemic salvage targeted anti-prostate specific membrane antigen radioimmunotherapy. *Advances in Urology* 2012, *accepted*

Invited Contributions

1. **Tagawa ST**. Thrombosis in cancer: A review of epidemiology, plasma markers of hemostatic activation, fibrinolysis, and angiogenesis, and the potential use of heparins. *Recent Res Devel Cancer* 2004; 6(2): 295-310.
2. Arnason J, **Tagawa ST**, Bander NH. New and newer vascular targets in oncology. Commentary on "Molecular Targets on Blood Vessels for Cancer Therapies in Clinical Trials". *Oncology* 2007; 21: 1376-80.

Scott T. Tagawa, MD

3. **Tagawa ST**. Editorial Comment: "Phase II trial of paclitaxel, carboplatin, and gemcitabine in patients with locally advanced carcinoma of the bladder". *J Urol* 2008; Oct 16 [E Pub Ahead of Print]
4. **Tagawa ST**. Editorial Comment: "Sequential use of sorafenib and sunitinib in a series of 90 consecutive patients with renal cell carcinoma". *J Urol* July 2009; 182:34.
5. **Tagawa ST**. Editorial Comment: "Adjuvant chemotherapy for high-risk upper tract urothelial carcinoma: Results from the Upper Tract Urothelial Carcinoma Consortium". *J Urol* September 2009; 182: 906.
6. Beltran H, Nanus DM, **Tagawa ST**. Beyond the Abstract - Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer. *UroToday.com*, July 30, 2010.
http://www.urotoday.com/3341/browse_categories/beyond_the_abstract/beyond_the_abstract_carboplatin_plus_paclitaxel_therapy_after_docetaxel_in_men_with_metastatic_castrate_resistant_prostate_cancer_by_himisha_beltran_md_et_al07302010.html#showcomments
7. Akhtar NH, **Tagawa ST**. Editorial Comment: "The Value of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy". *J Urol* 2011; 185 Nov 11 [Epub ahead of print]
8. **Tagawa ST**. Boning up on prognostic factors in advanced renal cell carcinoma. *Ann Oncol* 2011; 22: 751-3.
9. Dubin JM, Chromecki TF, Beltran H, Goldenberg S, Cha EK, Karakiewicz PI, Zeltser IS, Scherr DS, **Tagawa ST**, Shariat SF. Management of Castration-Resistant Prostate Cancer in 2011. *Ann Urol* 2011 [Epub ahead of print]
10. Lee DJ, Cha EK, Dubin JM, Beltran H, Scherr DS, **Tagawa ST**, Shariat SF. Novel Therapeutics for the Management of Castration-Resistant Prostate Cancer. *BJU Int* 2011; Epub ahead of print
11. **Tagawa ST**, Beltran H. Abiraterone plus prednisone improves survival in metastatic castration resistant prostate cancer. *As J Andrology* 2011; advance online publication doi:10.1038/aja.2011.113
12. Beltran H, **Tagawa ST**. Editorial Comment: "Detection of Metastatic Disease as A Leading Cause of Screening Failure in A Phase III Trial of Zibotentan Versus Placebo in Patients with Non-Metastatic Castration- Resistant Prostate Cancer (CRPC)". *J Urol* 2012, accepted
13. Osborne JR, Akhtar NH, Vallabhajosula S, Anand A, Deh K, **Tagawa ST**. Prostate specific membrane antigen imaging. *Urol Oncol* 2012 in revision

Books and Chapters in Books

1. **Tagawa ST**, Hamid O, Skinner E, Kumar P. Uncommon Cancers of the Prostate. In *Textbook of Uncommon Cancers, 3rd Ed*. Raghavan D et al. Eds. Wiley & Sons, Ltd, 2006.
2. Bander NH, Vallabhajosula S, Goldsmith SJ, **Tagawa ST**, Nanus DN. Targeted Radionuclide Therapy for Prostate Cancer. In *Targeted Radionuclide Therapy*. Speer TW Ed. Lippincott Williams & Wilkins, 2010.
3. Beltran H and **Tagawa ST**. Overview of disease pathways and drug targets. In *Targeted Therapies for Castration-Resistant Prostate Cancer*. Scardino PT Ed. Future Medicine, Ltd, 2012.

Scott T. Tagawa, MD

4. Diamond E, Akhtar NH, **Tagawa ST**, Nanus DN. Chemotherapy in metastatic RCC: A targeted approach in non-clear-cell and sarcomatoid/rapidly progressive RCC. In *Targeted Therapies for Renal Cell Carcinoma*. Bukowski R Ed. Future Science Group, 2012.
5. **Tagawa ST**, Akhtar NH, Robinson BR, Beltran H. Uncommon Cancers of the Prostate. In *Textbook of Uncommon Cancers, 4th Ed*. Raghavan D et al. Eds. Wiley & Sons, Ltd, 2012.

Invited Lectures/Presentations

Hemostasis, Fibrinolysis, and Angiogenesis in Cancer and the Potential Use of Heparins. Hematology Grand Rounds, LAC+USC Medical Center, Los Angeles, CA, May, 2004.

Plasma Markers of Hemostatic Activation, Fibrinolysis, and Angiogenesis in Men with Localized and Advanced Carcinoma of the Prostate. Urology Grand Rounds, USC/Norris Comprehensive Cancer Center, Los Angeles, CA, October, 2005.

Chemotherapy for Carcinoma of the Prostate: An Update. Advanced Workshop in Urology: New Advances in the Treatment of Prostate Cancer, New York Academy of Medicine, March, 2006.

Thrombosis in Cancer. Grand Rounds, North Shore Medical Group
Huntington, New York, May, 2006

Therapy for Hormone Refractory Prostate Cancer: An Update, Medicine Grand Rounds, Mount Sinai School of Medicine, September, 2006

An Overview and Update of Medical Management of Kidney Cancer, Urology Grand Rounds, Mount Sinai School of Medicine, October, 2006

Hemostatic Activation, Fibrinolysis, and Angiogenesis in Prostate Cancer, Urology Grand Rounds, Weill-Cornell Medical College, January, 2007

New Therapies for Kidney Cancer, Division of Nephrology Grand Rounds, Mount Sinai School of Medicine, February, 2007

Chemotherapy for Carcinoma of the Prostate: An Update. Advanced Workshop in Urology: New Advances in the Treatment of Prostate Cancer, New York Academy of Medicine, April, 2007.

Controversies in Growth Factor Support for Hematologic Toxicities. New York, NY, January, 2008.

Controversies in Growth Factor Support for Hematologic Toxicities. New York Medical College, White Plains, NY, January, 2008.

Scott T. Tagawa, MD

Update on Targeted Medical Therapy for Kidney Cancer. Urology Grand Rounds, Weill Cornell Medical College, June, 2008.

Overview of GU clinical research at WCMC: Prostate Specific Membrane Antigen and Beyond. Hematology & Medical Oncology Grand Rounds, Weill Cornell Medical College, July, 2008

Chemotherapy for muscle-invasive and metastatic bladder cancer: Current practice and what's on the horizon. Current Trends in Genitourinary Malignancies, New York, NY, October, 2008.

Advances in systemic therapy for prostate cancer. Department of Urology Grand Rounds, Mount Sinai School of Medicine, New York, NY, October 2008.

When to refer a patient to medical oncology: Evidence based systemic approaches. Contemporary Management of Prostate Cancer, Jacksonville, FL, February 2009

Systemic Therapy for Advanced Prostate Cancer. Grand Rounds, The Angeles Clinic and Research Institute, Los Angeles, CA, July, 2009

Systemic Therapy for Advanced Prostate Cancer. Grand Rounds, Department of Radiation Oncology, Weill Cornell Medical College, September, 2009

Immunotherapy for the Treatment of Advanced Prostate Cancer. Sixth Annual Current Trends in Genitourinary Malignancies, New York, NY, October 2009.

Advances in systemic therapy for prostate cancer. Grand Rounds, Division of Hematology & Oncology, University of Cincinnati, April, 2010

Clinical Stage I Seminoma: Chemotherapy is the answer (debate). Seventh Annual Current Trends in Genitourinary Malignancies, New York, NY, October 2010.

Immunotherapy for Advanced Carcinoma of the Prostate. Seventh Annual Current Trends in Genitourinary Malignancies, New York, NY, October 2010.

Anti-Prostate Specific Membrane Antigen-based Radioimmunotherapy for Castration Resistant Prostate Cancer. Plenary Session: Therapeutics. Innovative Minds in Prostate Cancer Today (IMPACT) Conference. Orlando, FL, March, 2011.

Chemotherapy for prostate cancer: Recent advances. International Prostate Cancer Symposium, New York, NY, May 2011.

Chemotherapy for Bladder Cancer: Current Practice and What's On the Horizon. American Urologic Association, New York Section. Paris/Normandy, FR, Sept, 2011

Advances in systemic therapy for castration-resistant prostate cancer. American Urologic Association, New York Section. Paris/Normandy, FR, Sept, 2011

Scott T. Tagawa, MD

Society Memberships

American Society of Clinical Oncology
American Society of Hematology
American College of Physicians
American Urologic Association
American Association for Cancer Research

Editorial Boards

Urologic Oncology: Seminars and Original Investigations (May 2011 –)
Therapeutic Advances in Medical Oncology (Aug 2011 –)
Frontiers in Genitourinary Oncology (Sept 2011 –)
Annals of Oncology (Jan 2012 –)

Reviewer for Journals

Journal of Urology
American Journal of Hematology
The Oncologist
Annals of Oncology
Therapeutic Advances in Medical Oncology
Cancer Investigation
OncoTargets and Therapy
European Urology
Cancer

Addenda

Selected Abstract Presentations

1. El-Khoueiry AB, **Tagawa ST**, Quinn DI, Panares R, Tsao-Wei J, Stein JP, Skinner DG, Raghavan D. Adjuvant gemcitabine and cisplatin (GC) for locally advanced cancer of the bladder after radical cystectomy: A USC experience with molecular correlates. Poster Session, American Society of Clinical Oncology, May 2004, New Orleans, LA.
2. **Tagawa ST**, Dorff TB, Rochanda L, Ye W, Boyle S, Lieskovsky G, Skinner DG, Raghavan D, Quinn DI, Liebman HA. Hemostatic activation, fibrinolysis, and angiogenesis prior to radical prostatectomy: Prediction of bleeding and prognosis. Poster Session, Prostate Cancer Symposium, February 2007, Orlando, FL
3. **Tagawa ST**, Dorff TB, Rochanda L, Ye W, Hannoun D, Eiseler N, Lieskovsky G, Skinner DG, Liebman HA, Quinn DI. Subclinical hemostatic activation and surgical volume predict peri-operative bleeding with radical prostatectomy. Poster Session, American Society of Clinical Oncology, June 2007, Chicago, IL
4. **Tagawa ST**, Dorff TB, Rochanda L, Ye W, Lieskovsky G, Skinner DG, Quinn, DI, Liebman HA. Hemostatic activation, fibrinolysis, and angiogenesis prior to radical retropubic prostatectomy. Oral Presentation, Poster Discussion Session, 4th International

Scott T. Tagawa, MD

Conference on Thrombosis and Hemostasis issues in Cancer, October 2007, Bergamo, Italy

5. **Tagawa ST**, Jeske S, Milowsky MI, Matulich D, Kung S, Sung M, Lehrer D, Kaplan J, Nanus DM. Initial Results of NCI 6981: A Phase I/II Trial of Sorafenib (S) plus Gemcitabine (GEM) and Capecitabine (CAP) for Advanced Renal Cell Carcinoma (RCC). Poster Session, ASCO GU Symposium, February 2008, San Francisco, CA
6. Jeske SJ, Tu JJ, Darshan M, Levy B, Zhou K, **Tagawa ST**, Giannakakou PA, Nanus DM. Tubulin acetylation correlates with time to progression (TTP) in patients with metastatic castrate resistant prostate cancer (PC) receiving docetaxel-based chemotherapy. Poster Session, ASCO GU Symposium, February 2008, San Francisco, CA
7. Bander NH, **Tagawa ST***, Vallabhajosula S, Goldsmith S, Milowsky M, Morris M, Nanus DM. Phase 2a trial of ¹⁷⁷Lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (¹⁷⁷Lu-J591) in patients (pts) with metastatic androgen-independent prostate cancer (AIPC). Podium presentation, Annual Meeting of the American Urological Association, May 2008, Orlando, FL.
**presenting author*
8. **Tagawa ST**, Milowsky MI, Morris M, Vallabhajosula S, Goldsmith S, Matulich D, Kaplan J, Berger F, Scher H, Bander NH, Nanus DM. Phase II trial of ¹⁷⁷Lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (¹⁷⁷Lu-J591) in patients (pts) with metastatic castrate-resistant prostate cancer (metCRPC). Poster Presentation, American Society of Clinical Oncology 2008 Annual Meeting, Chicago, IL.
9. **Tagawa ST**, Jeske S, Milowsky MI, Vallabhajosula S, Goldsmith S, Matulich D, Kaplan J, Bander NH, Nanus DM. Updated results of a phase II trial of ¹⁷⁷Lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (¹⁷⁷Lu-J591) in patients (pts) with metastatic castrate-resistant prostate cancer (metCRPC). Oral Presentation, Twelfth Conference on Cancer Therapy with Antibodies and Immunoconjugates, Parsippany, NY.
10. **Tagawa ST**, Vallabhajosula S, Goldsmith SJ, Petrillo K, Matulich D, Kaplan J, Bander NH, Nanus DM. Phase I trial of fractionated-dose ¹⁷⁷Lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (¹⁷⁷Lu-J591) in patients (pts) with metastatic castrate-resistant prostate cancer (metCRPC). Poster Presentation, 2009 ASCO GU Symposium, Orlando, FL.
11. Levy B, **Tagawa ST**, Loftus M, Zhou XK, Giannakakou P, Nanus DM. Biomarkers analysis of circulating tumor cells in prostate cancer. Correlating response to taxanes – A pilot study. Poster Presentation, 2009 ASCO GU Symposium, Orlando, FL.
12. Hudes GR, **Tagawa ST**, Whang Y, Qi M, Qin X, Puchalski T, Prabhakar U, O'Brien K, Eisenberger M. A phase 1 study of CNTO 328, an anti-interleukin (IL)-6 monoclonal antibody combined with docetaxel (T) in subjects with metastatic castration resistant prostate cancer (CRPC). Poster Discussion, 2009 ASCO Annual Meeting, Orlando, FL.
13. **Tagawa ST**, Vallabhajosula S, Osborne J, Goldsmith SJ, Petrillo K, Selzer J, Nanus DM, Bander NH. Radiolabeled Anti-Prostate Specific Membrane Antigen J591 for Castrate-Resistant Prostate Cancer. Poster Presentation, 2009 Prostate Cancer Foundation Scientific Meeting, Lake Tahoe, NV
14. **Tagawa ST**, Vallabhajosula S, Osborne J, Beltran H, Petrillo K, Tyrell L, Selzer J, Goldsmith SJ, Bander NH, Nanus DM. Radiolabeled anti-prostate specific membrane

Scott T. Tagawa, MD

- antigen (PSMA) monoclonal antibody J591 for castration-resistant prostate cancer (CRPC). Poster Presentation, 2010 ASCO GU Cancers Symposium, San Francisco, CA
15. Arnason JE, Hong S, Levandovsky M, Dhillon GS, Banerjee S, Petrillo K, Selzer J, Nanus DM, **Tagawa ST**. Circulating markers of hemostatic activation, fibrinolysis and angiogenesis are increased in patients (pts) with metastatic prostate cancer (PC). Poster Presentation, 2010 ASCO GU Cancers Symposium, San Francisco, CA
 16. Arnason JE, Hong S, Dhillon GS, Banerjee S, Gorynski E, Levandovsky M, Petrillo K, Selzer J, Nanus DM, **Tagawa ST**. Hemostatic activation, fibrinolysis and angiogenesis are increased in patients with advanced prostate cancer (PC) and decrease in response to hormonal therapy. Oral Presentation, 5th International Conference on Thrombosis and Hemostasis Issues in Cancer, Stresa, IT.
 17. **Tagawa ST**, Vallabhajosula S, Osborne J, Goldsmith SJ, Petrillo K, Tyrell L, Dhillon GS, Beltran H, Bander NH, Nanus DM. Phase I trial of fractionated-dose ¹⁷⁷lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (¹⁷⁷Lu-J591) in patients (pts) with metastatic castration-resistant prostate cancer (metCRPC). Poster Presentation, American Society of Clinical Oncology 2010 Annual Meeting, Chicago, IL
 18. **Tagawa ST**, Weitz IC, O'Connell CL, Rochanda L, Archer M, Quinn DI, Liebman HA. Tinzaparin Is Effective and Safe for the Treatment and Extended Secondary Prophylaxis In Cancer Patients with Venous Thromboembolism. Poster presentation, American Society of Hematology 2010 Annual Scientific Meeting, Orlando, FL
 19. Akhtar NH, Nanus DM, Vallabhajosula S, Osborne J, Beltran H, Tyrell L, Nadeau K, Saran A, Mileo G, Goldsmith SJ, Bander NH, **Tagawa ST**. Anti-prostate specific membrane antigen (PSMA)-based radioimmunotherapy: A combined analysis of radiolabeled-J591 studies. Poster Presentation, 2011 Genitourinary Cancers Symposium, Orlando, FL

Selected Abstract Publications

1. El-Khoueiry AB, **Tagawa ST**, Quinn DI, Panares R, Tsao-Wei D, Stein JP, Skinner DG, Raghavan D. Adjuvant gemcitabine and cisplatin (GC) for locally advanced cancer of the bladder after radical cystectomy: A USC experience with molecular correlates. *J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition)*; 22(14S): Abst 4639
2. **Tagawa ST**, Dorff TB, Rochanda L, Ye W, Hannoun D, Eiseler N, Lieskovsky G, Skinner DG, Liebman HA, Quinn DI. Subclinical hemostatic activation and surgical volume predict peri-operative bleeding with radical prostatectomy. *J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part 1*; 25(18S): 268s (Abst 5136)
3. **Tagawa ST**, Dorff TB, Rochanda L, Ye W, Lieskovsky G, Skinner DG, Quinn DI, Liebman HA. Hemostatic activation, fibrinolysis, and angiogenesis prior to radical retropubic prostatectomy. *Thrombosis Research* 2007; 120 (Suppl 2): S150 (Abst PO16)
4. **Tagawa ST**, Jeske S, Milowsky MI, Matulich D, Kung S, Sung M, Lehrer D, Kaplan J, Nanus DM. Initial Results of NCI 6981: A Phase I/II Trial of Sorafenib (S) plus Gemcitabine (GEM) and Capecitabine (CAP) for Advanced Renal Cell Carcinoma (RCC). *Proceedings of the 2008 Genitourinary Cancers Symposium*

Scott T. Tagawa, MD

5. Jeske SJ, Tu JJ, Darshan M, Levy B, Zhou K, **Tagawa ST**, Giannakakou PA, Nanus DM. Tubulin acetylation correlates with time to progression (TTP) in patients with metastatic castrate resistant prostate cancer (PC) receiving docetaxel-based chemotherapy. *Proceedings of the 2008 Genitourinary Cancers Symposium*.
6. Bander NH, Nanus DM, **Tagawa ST**, Vallabhajosula S, Goldsmith S, Milowsky M, Morris M. Phase 2a trial of ¹⁷⁷Lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (¹⁷⁷Lu-J591) in patients (pts) with metastatic androgen-independent prostate cancer (AIPC). *J Urol* 2008; 179(4Suppl): 253 (Abst 724)
7. **Tagawa ST**, Milowsky MI, Morris M, Vallabhajosula S, Goldsmith S, Matulich D, Kaplan J, Berger F, Scher H, Bander NH, Nanus DM. Phase II trial of ¹⁷⁷Lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (¹⁷⁷Lu-J591) in patients (pts) with metastatic castrate-resistant prostate cancer (metCRPC). *J Clin Oncol 2008 ASCO Annual Meeting Proceedings Part 1*; 26(15S): 284s (Abst 5140)
8. Jeske S, **Tagawa ST**, Milowsky MI, Matulich D, Kung S, Sung M, Lehrer D, Kaplan J, Nanus DM. Sorafenib (S) plus Gemcitabine (GEM) and Capecitabine (CAP) for Advanced Renal Cell Carcinoma (RCC): Updated phase I results from a phase I/II trial (NCI 6981). *J Clin Oncol 2008 ASCO Annual Meeting Proceedings Part 1*; 26(15S): 672s (Abst 16023)
9. Hynecek R, Goldsmith SJ, Vallabhajosula S, Nanus D, **Tagawa S**, Bander N. ¹⁷⁷Lu-J591 monoclonal antibody (Lu-J591) therapy in metastatic castrate-resistant prostate cancer (metCRPC): Correlation of antibody-tumor targeting and treatment response. *J Nuc Med* 2008; 49 (Suppl 1): 144P
10. **Tagawa ST**, Vallabhajosula S, Goldsmith SJ, Petrillo K, Matulich D, Kaplan J, Bander NH, Nanus DM. Phase I trial of fractionated-dose ¹⁷⁷Lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (¹⁷⁷Lu-J591) in patients (pts) with metastatic castrate-resistant prostate cancer (metCRPC). *Proceedings of the 2009 Genitourinary Cancers Symposium*
11. Levy B, **Tagawa ST**, Loftus M, Zhou XK, Giannakakou P, Nanus DM. Biomarkers analysis of circulating tumor cells in prostate cancer. Correlating response to taxanes – A pilot study. *Proceedings of the 2009 Genitourinary Cancers Symposium*.
12. Hudes GR, **Tagawa ST**, Whang Y, Qi M, Qin X, Puchalski T, Prabhakar U, O'Brien K, Eisenberger M. A phase 1 study of CNTO 328, an anti-interleukin (IL)-6 monoclonal antibody combined with docetaxel (T) in subjects with metastatic castration resistant prostate cancer (CRPC). *Proceedings of the 2009 Genitourinary Cancers Symposium*.
13. **Tagawa ST**, Parmar S, Pena J, Petrillo K, Matulich D, Selzer J, Vallabhajosula S, Goldsmith SJ, Bander NH, Nanus DM. Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 in patients (pts) with metastatic castrate-resistant prostate cancer (metCRPC). *J Clin Oncol* 27, 2009 (suppl; abstr e16004)
14. Bradley D, Daignault S, Smith DC, Nanus D, **Tagawa S**, Stadler WM, Garcia J, Dreicer R, Al-Hawary M, Hussain M. Maintenance sunitinib postchemotherapy (CT) in patients (pts) with advanced urothelial carcinoma (UC): A randomized placebo controlled phase II trial. *J Clin Oncol* 27:15s, 2009 (suppl; abstr 5073)
15. Hudes G, **Tagawa S**, Whang Y, Qi M, Qin X, Puchalski T, Prabhakar U, O'Brien K, Eisenberger M. A phase I study of CNTO328, an anti-interleukin (IL)-6 monoclonal

Scott T. Tagawa, MD

- antibody combined with docetaxel in subjects with metastatic castration-resistant prostate cancer (CRPC). *J Clin Oncol* 27:15s, 2009 (suppl; abstr 5063)
16. Arnason JE, Hong S, Dhillon GS, Banerjee S, Gorynski E, Levandovsky M, Petrillo K, Selzer J, Nanus DM, **Tagawa ST**. Hemostatic activation, fibrinolysis and angiogenesis are increased in patients with advanced prostate cancer (PC) and decrease in response to hormonal therapy. *Thrombosis Res* 2010; 125 (suppl 2): S165
 17. **Tagawa ST**, Vallabhajosula S, Osborne J, Goldsmith SJ, Petrillo K, Tyrell L, Dhillon GS, Beltran H, Bander NH, Nanus DM. Phase I trial of fractionated-dose ¹⁷⁷lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (¹⁷⁷Lu-J591) in patients (pts) with metastatic castration-resistant prostate cancer (metCRPC). *J Clin Oncol* 28:7s, 2010 (suppl; abstr 4667)
 18. Akhtar NH, Nanus DM, Vallabhajosula S, Osborne J, Beltran H, Tyrell L, Nadeau K, Saran A, Mileo G, Goldsmith SJ, Bander NH, **Tagawa ST**. Anti-prostate specific membrane antigen (PSMA)-based radioimmunotherapy: A combined analysis of radiolabeled-J591 studies. *J Clin Oncol* 2011; 29 (suppl 7; abstr 136)

Research Certification

NCI Investigator No. 38694

Health Information Portability and Accountability Act Certification of Training, University of Southern California, 2000

Understanding the Fundamentals: Responsibilities and Requirements for the Protection of Human Subjects in Research, University of Southern California, February, 2003

Human Participants Protection for Research Teams, National Institutes of Health, July, 2005

Health Information Portability and Accountability Act Certification of Training, Mount Sinai School of Medicine, August, 2005

Investigator Training Certificate, Bristol-Myers Squibb, April, 2006

Protection of Human Research Subjects, CITI, April, 2007; Refresher Course May, 2011

Health Information Portability and Accountability Act Certification of Training, Weill Cornell Medical College, April, 2007

Investigator Training Certificate, Sanofi-Aventis, November, 2007

Research Compliance: Grants & Contracts, Health Care Compliance Strategies, Inc., July, 2008

Merck Investigator Training, April, 2009

Clinical Trials (Current and Pending as of October, 2011)

Scott T. Tagawa, MD

Markers of hemostatic activation, fibrinolysis and angiogenesis in localized and advanced carcinoma of the prostate [closed to enrollment]

Role: Principal Investigator

NCI 6981: A Phase I/II Trial of BAY 43-9006 plus Gemcitabine and Capecitabine in the Treatment of Patients with Advanced Renal Cell Carcinoma [closed to enrollment]

Role: Study Chair

NCI 6896: A Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Combination with Isotretinoin (13-cis Retinoic Acid, 13- CRA) in the Treatment of Patients with Advanced Renal Cell Carcinoma. [closed to enrollment]

Role: Co-Investigator

A Phase 2 Trial of ¹⁷⁷Lu Radiolabeled Monoclonal Antibody HuJ591-GS (¹⁷⁷Lu-J591) in Patients with Metastatic Castrate Resistant Prostate Cancer

Role: Study Chair

Radioimmunotherapy Phase I Dose-Escalation Studies in Prostate Cancer using ¹⁷⁷Lu-J591 Antibody: Dose Fractionation Regimen

Role: Principal Investigator

A randomized, double-blinded placebo controlled phase III trial comparing docetaxel and prednisone with and without bevacizumab (IND #7921, NSC #704865) in men with hormone refractory prostate cancer (CALGB 90401) [study closed to enrollment]

Role: Principal Investigator

A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma (ECOG 2805) [study closed to enrollment]

Role: Co-Investigator

A multicenter, randomized double-blind phase II/III study in the first-line treatment of advanced transitional cell carcinoma (TCC) of the urothelium comparing vinflunine/gemcitabine to placebo/gemcitabine in patients who are ineligible to receive cisplatin-based therapy. [study closed to enrollment]

Role: Principal Investigator

Randomized Phase II Trial of Maintenance SU011248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma [closed to enrollment]

Role: Co-Investigator

Tinzaparin for primary treatment and extended secondary prophylaxis of venous thromboembolism in patients with cancer.

Role: Principal Investigator

A Multicenter, Open-Label, Randomized, Phase III Trial Comparing Immediate Adjuvant Hormonal Therapy (ELIGARD®- leuprolide acetate) in Combination with TAXOTERE® (docetaxel) Administered Every Three Weeks Versus Hormonal Therapy Alone Versus Deferred Therapy Followed by the Same Therapeutic Options in Patients with Prostate Cancer at High Risk of Relapse After Radical Prostatectomy [study closed to enrollment]

Role: Principal Investigator

A Phase I Study of a Chimeric Antibody Against Interleukin-6 (CNTO 328) Combined with Docetaxel in Subjects with Metastatic Hormone-Refractory Prostate Cancer [study closed to enrollment]

Role: Principal Investigator

A randomized double-blind, placebo-controlled phase III study of early versus standard

Scott T. Tagawa, MD

zoledronic acid to prevent skeletal related events in men with prostate cancer metastatic to bone (CALGB 90202)

Role: Principal Investigator

A randomized phase III study of neo-adjuvant docetaxel and androgen deprivation prior to radical prostatectomy versus immediate radical prostatectomy in patients with high-risk, clinically localized prostate cancer (CALGB 90203)

Role: Principal Investigator

A Global, Multicenter, Open-Label, Single Agent, Two-stage Phase 2 Study to Evaluate the Efficacy and Safety of AMG 102 in Subjects with Advanced Renal Cell Carcinoma

Role: Principal Investigator [study closed to enrollment]

A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy [study closed to enrollment]

Role: Principal Investigator

A Phase II Study of PHA-739358 in Patients with Metastatic Hormone Refractory Prostate Cancer [study closed to enrollment]

Role: Principal Investigator

Phase III study of docetaxel and atrasentan versus docetaxel and placebo for patients with advanced hormone refractory prostate cancer (SWOG S0421) [study closed to enrollment]

Role: Principal Investigator

Randomized Study of LAROTAXEL + Cisplatin (LC) vs. Gemcitabine + Cisplatin (GC) in the First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer [study closed to enrollment]

Role: Principal Investigator

A Randomized Phase II Study of Ridaforolimus (MK-8669) in Pain-Free or Mildly Symptomatic Patients With Hormone-Resistant Prostate Cancer [study closed to enrollment]

Role: Principal Investigator

A Randomized Phase 2 Trial of ¹⁷⁷Lu Radiolabeled Monoclonal Antibody J591 (¹⁷⁷Lu-J591) and ketoconazole in Patients with High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy

Role: Study Chair

A Pilot Study of ¹⁷⁷Lu Radiolabeled Monoclonal Antibody HuJ591-GS (¹⁷⁷Lu-J591) in Patients with Nonprostate Metastatic Solid Tumors

Role: Study Chair

A phase I trial of docetaxel/prednisone plus fractionated ¹⁷⁷Lu-J591 anti-prostate-specific membrane antigen monoclonal antibody in patients with metastatic, castrate-resistant prostate cancer

Role: Study Chair

Prognostic Significance of Circulating Tumor Cells in Prostate Cancer : A Pilot Study

Role: Co-Investigator

Phase I open-label, dose escalation study to determine the maximum tolerated dose and to evaluate the safety profile of lenalidomide (Revlimid, CC-5013) with every three week docetaxel (Taxotere) in subjects with androgen independent prostate cancer [closed to enrollment]

Role: Principal Investigator

Scott T. Tagawa, MD

Analysis of circulating tumor cells in prostate cancer predicting response to taxanes: a pilot study
Role: Co-Investigator

A phase III trial of short term androgen deprivation with pelvic lymph node or prostate bed only radiotherapy (SPPORT) in prostate cancer patients with a rising PSA after radical prostatectomy (RTOG 0534)
Role: Co-Investigator

VEG108844: A study of pazopanib versus sunitinib in the treatment of subjects with locally advanced and/or metastatic renal cell carcinoma [study closed to enrollment]
Role: Co-Investigator

A Phase III Study of Axitinib versus Sorafenib as Second-line Therapy for Metastatic Renal Cell Cancer: the AXIS trial [study closed to enrollment]
Role: Co-Investigator

CALGB 90601: A randomized double-blinded phase III study comparing gemcitabine, cisplatin, and bevacizumab to gemcitabine, cisplatin, and placebo in patients with advanced transitional cell carcinoma.
Role: Principal Investigator

AFFIRM: A multinational phase 3, randomized, double-blind, placebo-controlled efficacy and safety study of oral MDV3100 in patients with progressive castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy [closed to enrollment]
Role: Principal Investigator

A randomized, double-blind, phase III trial comparing ipilimumab versus placebo following radiotherapy in subjects with castration resistant prostate cancer that have failed prior treatment with docetaxel
Role: Principal Investigator

An open-label, single-arm, Phase II trial of intravenous BI 6727 in patients with locally advanced, metastatic or recurrent urothelial cancer of the bladder, renal pelvis, or ureters after failure of prior chemotherapy [study closed to enrollment]
Role: Principal Investigator

NCI 7659: A randomized study of GW786034 (pazopanib) in stage D0 relapsed androgen sensitive prostate cancer following limited GnRH agonist therapy [closed to enrollment]
Role: Principal Investigator

A Phase I/II, Open-Label, Dose-Escalation Study of CDX-1401 in Patients with Malignancies Known to Express NY-ESO-1
Role: Co-Investigator

A Phase II, Open-Label, Controlled, Randomized Study of the CDX-1307 Vaccine Regimen as Neoadjuvant and Adjuvant Therapy in Patients with Newly Diagnosed Muscle-Invasive Bladder Cancer Expressing hCG- β [closed to enrollment]
Role: Principal Investigator

A phase 3 study to evaluate the efficacy and safety of docetaxel and prednisone with or without lenalidomide in subjects with castrate-resistant prostate cancer [closed to enrollment]
Role: Principal Investigator

VEG113387: A Phase III Study to Evaluate Efficacy and Safety of Votrient in Patients with Localized RCC Following Nephrectomy
Role: Co-Investigator

A Phase 3, Randomized, Double-blind, Multicenter Trial Comparing TAK 700 plus Prednisone with

Scott T. Tagawa, MD

Placebo plus Prednisone in Patients with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Role: Principal Investigator

An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination with Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Role: Principal Investigator

A Randomized, Blinded, Phase 2 Dose-Ranging Study of BMS-936558 (MDX-1106) in Subjects With Progressive Advanced/Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy [closed to enrollment]
Role: Principal Investigator

A Phase 1b Safety Study of Abiraterone Acetate (JNJ-212082) and Docetaxel in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Role: Co-Investigator

CALGB 70807 – The Men’s eating and Living (MEAL) Study: A Randomized Trial of Diet to Alter Disease Progression in Prostate Cancer Patients on Active Surveillance
Role: Principal Investigator